Global injectable drugs market will reach $1,037.7 billion by 2030, growing by 9.8% annually over 2020-2030 driven by the increasing prevalence of chronic diseases, rising use of self-administered Injectable formulations, technological advancements in drug development, and growing approvals of new injectable drugs such as COVID-19 vaccines.
Highlighted with 82 tables and 86 figures, this 165-page report 鈥淕lobal Injectable Drugs 麻豆原创 2020-2030 by Molecule Type (Small, Large), Drug Class (mAbs, Immunoglobulin, Insulin, Vaccines, Cytokines, Peptide Hormone, Blood Factors), Delivery (Pre-filled Syringe, Infusions, Others), Application (Oncology, Infectious Diseases, Autoimmune, Cardiovascular), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce), and Region: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire global injectable drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global injectable drugs market in every aspect of the classification from perspectives of Molecule Type, Drug Class, Delivery, Application, Distribution Channel, and Region.
Based on Molecule Type, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
鈥� Small Molecule
鈥� Large Molecule
Based on Drug Class, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
鈥� Monoclonal Antibodies (mAbs)
鈥� Immunoglobulin
鈥� Insulin
鈥� Vaccines
鈥� Cytokines
鈥� Peptide Hormone
鈥� Blood Factors
鈥� Other Drug Classes
Based on Delivery, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
鈥� Pre-filled Syringe
鈥� Infusions
鈥� Other Deliveries
Based on Application, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
鈥� Oncology
鈥� Infectious Diseases
鈥� Autoimmune Diseases
鈥� Cardiovascular Diseases
鈥� Pain
鈥� Neurology
鈥� Other Applications
Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
鈥� Hospital Pharmacy
鈥� Retail Pharmacy
鈥� E-Commerce
Geographically, the following regions together with the listed national/local markets are fully investigated:
鈥� North America (U.S., Canada, and Mexico)
鈥� Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
鈥� APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
鈥� South America (Brazil, Chile, Argentina, Rest of South America)
鈥� MEA (UAE, Saudi Arabia, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Molecule Type, Drug Class, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Amgen Inc.
Baxter International Inc.
Eli Lilly and Company
Gilead Sciences Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co. Inc.
Moderna, Inc.
Novartis AG
Novo Nordisk AS
Pfizer Inc.
Sanofi SA
Teva Pharmaceuticals Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of 麻豆原创 Research Methodology 13
1.2.2 麻豆原创 Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 麻豆原创 Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 麻豆原创 Overview and Dynamics 21
2.1 麻豆原创 Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the 麻豆原创 25
2.2 Major Growth Drivers 27
2.3 麻豆原创 Restraints and Challenges 32
2.4 Emerging Opportunities and 麻豆原创 Trends 35
2.5 Porter鈥檚 Fiver Forces Analysis 39
3 Segmentation of Global 麻豆原创 by Molecule Type 43
3.1 麻豆原创 Overview by Molecule Type 43
3.2 Small Molecule 45
3.3 Large Molecule 46
4 Segmentation of Global 麻豆原创 by Drug Class 47
4.1 麻豆原创 Overview by Drug Class 47
4.2 Monoclonal Antibodies (mAbs) 49
4.3 Immunoglobulin 50
4.4 Insulin 51
4.5 Vaccines 52
4.6 Cytokines 53
4.7 Peptide Hormone 54
4.8 Blood Factors 55
4.9 Other Drug Classes 56
5 Segmentation of Global 麻豆原创 by Delivery 57
5.1 麻豆原创 Overview by Delivery 57
5.2 Pre-filled Syringe 59
5.3 Infusions 60
5.4 Other Deliveries 61
6 Segmentation of Global 麻豆原创 by Application 62
6.1 麻豆原创 Overview by Application 62
6.2 Oncology 64
6.3 Infectious Diseases 65
6.4 Autoimmune Diseases 66
6.5 Cardiovascular Diseases 67
6.6 Pain 68
6.7 Neurology 69
6.8 Other Applications 70
7 Segmentation of Global 麻豆原创 by Distribution Channel 71
7.1 麻豆原创 Overview by Distribution Channel 71
7.2 Hospital Pharmacy 73
7.3 Retail Pharmacy 74
7.4 E-Commerce 75
8 Segmentation of Global 麻豆原创 by Region 76
8.1 Geographic 麻豆原创 Overview 2019-2030 76
8.2 North America 麻豆原创 2019-2030 by Country 80
8.2.1 Overview of North America 麻豆原创 80
8.2.2 U.S. 84
8.2.3 Canada 87
8.2.4 Mexico 89
8.3 European 麻豆原创 2019-2030 by Country 91
8.3.1 Overview of European 麻豆原创 91
8.3.2 Germany 95
8.3.3 U.K. 97
8.3.4 France 99
8.3.5 Spain 101
8.3.6 Italy 103
8.3.7 Russia 105
8.3.8 Rest of European 麻豆原创 108
8.4 Asia-Pacific 麻豆原创 2019-2030 by Country 110
8.4.1 Overview of Asia-Pacific 麻豆原创 110
8.4.2 Japan 114
8.4.3 China 117
8.4.4 Australia 119
8.4.5 India 121
8.4.6 South Korea 123
8.4.7 Rest of APAC Region 125
8.5 South America 麻豆原创 2019-2030 by Country 127
8.5.1 Argentina 130
8.5.2 Brazil 132
8.5.3 Chile 134
8.5.4 Rest of South America 麻豆原创 136
8.6 MEA 麻豆原创 2019-2030 by Country 137
8.6.1 UAE 140
8.6.2 Saudi Arabia 142
8.6.3 South Africa 144
8.6.4 Other National 麻豆原创s 146
9 Competitive Landscape 147
9.1 Overview of Key Vendors 147
9.2 New Product Launch, Partnership, Investment, and M&A 150
9.3 Company Profiles 151
Amgen Inc. 151
Baxter International Inc. 153
Eli Lilly and Company 154
Gilead Sciences Inc. 155
GlaxoSmithKline PLC 156
Johnson & Johnson 157
Merck & Co. Inc. 158
Moderna, Inc. 159
Novartis AG 160
Novo Nordisk AS 161
Pfizer Inc. 162
Sanofi SA 163
Teva Pharmaceuticals Industries Ltd. 164
RELATED REPORTS 165
Key Players (this may not be a complete list and extra companies can be added upon request):
Amgen Inc.
Baxter International Inc.
Eli Lilly and Company
Gilead Sciences Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co. Inc.
Moderna, Inc.
Novartis AG
Novo Nordisk AS
Pfizer Inc.
Sanofi SA
Teva Pharmaceuticals Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
听
听
*If Applicable.
